Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. This disease has currently affected more than 346 million people and resulted in more than 5.5 million deaths in many countries. Neutralising monoclonal antibodies (MAbs) against the SARS-CoV-2 virus could serve as prophylactic/therapeutic agents in COVID-19 infection by providing passive protection against the virus in individuals. Until now, no Food and Drug Administration/European Medicines Agency-approved neutralising MAb against SARS-CoV-2 virus exists in the market, though a number of MAbs have been authorised for emergency use. Therefore, there is an urgent need for development of efficient anti-SARS-CoV-2 neutralising MAbs for use in the clinic. Moreover, neutralising anti-SARS-CoV-2 MAbs could be used as beneficial tools for designing epitope-based vaccines against the virus. Given that the target epitope of a MAb is a crucial feature influencing its neutralising potency, target epitopes of neutralising anti-SARS-CoV-2 MAbs already reported in the literature and reactivity of these MAbs with SARS-CoV-2 variants are reviewed herein.
Keywords: COVID-19; RBD; SARS-CoV-2 virus; epitope mapping; immunotherapy; neutralising monoclonal antibody.
【저자키워드】 COVID-19, Immunotherapy, SARS-CoV-2 virus, RBD, epitope mapping, neutralising monoclonal antibody., 【초록키워드】 coronavirus disease, SARS-CoV-2, coronavirus, pandemic, monoclonal antibody, SARS-CoV-2 variant, drug, virus, anti-SARS-CoV-2, Medicine, COVID-19 infection, death, epitope, disease, Emergency use, food, Epitope-based vaccine, acute respiratory syndrome, neutralising, affected, reported, individuals, reactivity, neutralising MAb, the SARS-CoV-2 virus, 【제목키워드】 Vaccine design, anti-SARS-CoV-2, monoclonal, neutralising,